Mumbai-based Sun Pharmaceutical Industries has announced that one of its wholly-owned subsidiaries has entered into a license agreement with Pharmazz Inc., a US-based biopharmaceutical company to commercialise a first-in-class innovative drug, Tyvalzi™ (Sovateltide) in India. Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke.

As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide). Pharmazz will be entitled to upfront and milestone payments, including royalties.

According to Kirti Ganorkar, CEO -India Business, Sun Pharma, “The Phase 3 clinical trial for Tyvalzi™ conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke. Tyvalzi™ is a first-in-class innovative drug which can help improve the quality of life of stroke patients. The drug can be administered within 24 hours for the treatment of ischemic stroke. The current treatment options provide a narrow time window of 4-5 hours limiting its use in most patients.”

Stroke is the fourth leading cause of death and the fifth leading cause of disability in India. By 2050, more than 80% of the predicted global burden of new strokes of 15 million will occur in low and middle-income countries.